Displaying all 3 publications

Abstract:
Sort:
  1. Exploring the cholesterol-lowering effects of cereal bran cell wall-enriched diets
    Tufail T, Saeed F, Tufail T, Bader Ul Ain H, Hussain M, Noreen S, et al.
    Food Sci Nutr, 2024 Jul;12(7):4944-4951.
    PMID: 39055199 DOI: 10.1002/fsn3.4141
    Cell wall polysaccharides (dietary fiber) in cereal grains contribute to health benefits. The novelty of the current study was an effort to explore the in vivo therapeutic potential of different cereal bran cell walls against hypercholesterolemia. For this purpose, the cell walls were isolated from different cereal brans (wheat, maize, oats, and barley), and the intake of these cereal bran cell walls was evaluated for their anti-lipidemic activity in normal and hypercholesterolemic rats. The serum taken from the rats was tested for cholesterol, lipid, and triglyceride profiles before and after treatment. The outcomes of the current study have shown that the cereal cell wall has a significant hypercholesterolemia effect. The biochemical parameters of the control animals were within the normal clinical ranges, indicating that the experimental diets were safe. Among cereal bran cell walls, barley bran significantly decreased cholesterol (56.35 ± 1.35 mg/dL), low-density lipoprotein (56.35 ± 1.05 mg/dL), triglycerides (105.29 ± 1.95 mg/dL), and increased high-density lipoprotein level (48.35 ± 1.35 mg/dL). These findings provide conclusive evidence that the cereal cell wall is beneficial in the treatment of hypercholesterolemia and may potentially provide protection against other acute, recurring, or chronic illnesses.
  2. Functionalization and optimization of biopolymer encapsulants for controlled release in food systems
    Kaseke T, Shinga MH, Kha TC, Tran THP, Ashraf J, Tufail T, et al.
    J Microencapsul, 2026 Nov 02.
    PMID: 42969875 DOI: 10.1080/02652048.2026.2753596
    The growing interest in biopolymer encapsulants offers a sustainable alternative to synthetic packaging, addressing concerns over plastic pollution and microplastic-related health risks while improving bioactive compound stability. However, poor moisture barrier properties, low mechanical strength, and high production costs hinder their large-scale applications. To address these challenges, chemical and physical functionalization techiques have been developed to enhance material performance, encapsulation efficiency, and the overall functionality of core materials in food applications. Chemical modifications, including cross-linking, grafting, Maillard reactions, phosphorylation, and carboxymethylation, alongside physical approaches such as blending, coating, and nanoparticle incorporation, have significantly improved material performance, stability, and controlled release of bioactives in food systems. Additionally, emerging tools such as machine learning show potential for optimising functionalization processes and predicting performance outcomes. Despite these advances, challenges related to scalability, regulatory compliance, and consumer acceptance persist. Overall, functionalized biopolymers present a promising pathway towards sustainable, high-performance food packaging and delivery systems.
  3. Fulltext Global Burden of Anorexia Nervosa and Bulimia Nervosa, 1990 to 2023, With Forecasts to 2050: A Global Burden of Disease Study 2023 Analysis
    Bai R, Dong W, Wang X, Zhang A, Santomauro DF, GBD Eating Disorders Collaborators, et al.
    JAMA Psychiatry, 2026 Oct 28.
    PMID: 42949727 DOI: 10.1001/jamapsychiatry.2026.3457
    IMPORTANCE: Eating disorders are a major cause of nonfatal mental health burden, yet global evidence on their long-term trends, geographic distribution, and future trajectories remains limited.

    OBJECTIVE: To estimate the global, regional, and national prevalence and disability burden of anorexia nervosa and bulimia nervosa-and mortality attributable to anorexia nervosa-from 1990 to 2023, and to forecast prevalence to 2050.

    DESIGN, SETTING, AND PARTICIPANTS: Using Global Burden of Disease (GBD) 2023 methods, data were synthesized from systematic literature reviews, population surveys, and vital registration systems. Estimates were produced for 204 countries and territories from 1990 to 2023, with forecasts through 2050. These data were analyzed from October 2025 to August 2026.

    EXPOSURE: Anorexia nervosa or bulimia nervosa diagnosis.

    MAIN OUTCOMES AND MEASURES: Counts and age-standardized rates with 95% uncertainty intervals (UIs) for anorexia nervosa and bulimia nervosa prevalence, years lived with disability (YLDs), and disability-adjusted life-years (DALYs), and anorexia nervosa mortality, reported by age, sex, and location.

    RESULTS: In 2023, an estimated 18.1 million people (95% UI, 13.9-24.0) globally were living with anorexia nervosa or bulimia nervosa, of whom 12.6 million (69.4%) were female, 5.5 million were male (30.6%), and 41.2% were aged 10 to 24 years. These cases accounted for 3.83 million DALYs (95% UI, 2.23-5.69). Since 1990, the global number of prevalent cases increased by 71.0%, while age-standardized prevalence and DALY rates rose by about 21%. Females experienced substantially higher prevalence and DALY rates than males. The highest age-standardized prevalence rates were observed in high-income regions, particularly Australasia and Western Europe, whereas the largest relative increases in age-standardized prevalence occurred in East Asia, South Asia, and Southeast Asia. Forecasts indicate continued increases in prevalent cases through 2050.

    CONCLUSIONS AND RELEVANCE: This GBD 2023 analysis found that anorexia nervosa and bulimia nervosa contribute substantially to global nonfatal health loss. These findings support the integration of eating disorders into mental health surveillance, prevention, and service planning worldwide.

Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links